Immune Mediated Disease Therapeutics Developer Attovia Therapeutics Debuts on Nasdaq

IPO/OfferingPositive

AI Analysis

Summary

Attovia Therapeutics, an immune-mediated disease therapeutics developer backed by Qiming Venture Partners, completed its Nasdaq IPO on August 5, 2026, issuing shares at $17.00 per share under ticker ATTO.

Outcome Details

Successfully listed on Nasdaq at $17.00 per share

Importance:7/10

Sentiment:

0.70

IPONasdaqImmuno-oncologyClinical-stage

Related Companies

$ATTO

Read the original article

Published by PR Newswire Biotech on August 6, 2026 10:23 AM

Read Original